Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taiwan Liposome Company, Ltd.

https://www.tlcbio.com/en-global

Latest From Taiwan Liposome Company, Ltd.

Cross-Strait Taiwan Tensions, COVID, And Clinical Trials: An Interview With TLC President Yeh

A recent survey showed healthcare as among the sectors US companies were most concerned about amid the ongoing China-US tensions over Taiwan. But how do biotech firms on the island itself view the current situation? We spoke to the president of one amid Taiwan’s imminent reopening.

Strategy Policy

TLC President On COVID, Cross-Strait Taiwan Tensions

A recent survey showed healthcare as the sector US public companies were most concerned about (after semiconductors) amid the ongoing China-US tensions over Taiwan. But how do biotech firms in Taiwan itself view the current situation? Scrip spoke to the president of one of the most innovative and active companies in the sector, amid the island’s imminent reopening to the world after over two long years under pandemic restrictions.

Policy Risk Management

Finance Watch: Inhibikase IPO Brought 2020 US Total To 86

Public Company Edition: The new year started with two companies signaling plans for significant near-term initial public offerings, following Inhibikase’s launch as the last IPO of 2020. Other recent financial highlights include layoffs at Calithera and Regenxbio’s $200m Zolgensma royalty sale.

Financing Business Strategies

Pneumagen Targeting The Human Glycome To Block Viral Entry

Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.

Emerging Company Profile Infectious Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • TLC Biopharmaceuticals Limited (TLCHK)
    • InspirMed
UsernamePublicRestriction

Register